Biosimilar News: U.S. FDA Expands Yuflyma’s Label to Include HS in Adolescents and UV in Kids
The US Food and Drug Administration (FDA) has approved expanded indications for adalimumab-aaty (Humira) biosimilar Yuflyma (Celltrion) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescents aged 12 and older, and uveitis (UV) in pediatric patients aged 2 and up.